Summary

The global market for aesthetic medicine and surgery has continued to show robust growth since 2020, with the market valued at $13.9 billion in 2022 and expected to grow at a CAGR of 11% to 2027 to reach around $23.4 billion. This growth is driven by the increasing importance attached to physical appearance, the acceptance of aesthetic procedures and technological advances. By 2021, non-surgical procedures accounted for 54% of the global market, with an estimated value of $7.5 billion. The United States remains the market leader, particularly for non-surgical procedures, with 5.3 million treatments performed in 2021.

Aesthetic medicine market trends in Italy

The aesthetic medicine landscape in Italy has evolved rapidly, with a number of socio-demographic factors such as an ageing population and a growing emphasis on physical appearance propelling market growth. The Italian aesthetic medicine market, estimated at around 160 million euros, is increasingly popular among younger Italians, who are turning to aesthetic treatments to treat the first signs of aging and to improve their overall appearance. In Italy, a large majority, between 80 and 90%, of aesthetic medicine procedures are requested by women. However, interest from men has grown considerably, with requests for non-surgical treatments increasing by over 25%. This shift towards a more diverse demographic can be attributed to the increasing normalization and acceptance of aesthetic treatments among both men and women. A significant proportion of demand in the Italian market comes from the 19-34 age group, which accounts for around 40-45% of procedures. This indicates a trend towards early adoption of aesthetic practices among young adults. The next age bracket, 35-50, follows closely behind with almost 35-40% of procedures, suggesting that preventive treatments are also in high demand among those approaching or in middle age. Injectable products, such as botulinum toxin and hyaluronic acid, are the main procedures, with their popularity extending to various demographic categories. However, interest in botulinum toxin is slightly eclipsed by demand for hyaluronic acid, suggesting a certain level of reticence among Italians due to concerns about the safety of botulinum toxin, despite its proven safety in numerous studies. In the facial rejuvenation segment, chemical peels and skin tightening represent substantial pockets of demand. Meanwhile, the "other" procedures segment is largely driven by permanent hair removal, followed by anti-cellulite treatments and non-surgical fat removal. These segments collectively contribute to the dynamic and evolving nature of the aesthetic medicine landscape in Italy. In addition, Italy has also become a destination for medical tourism, with between 10 and 15% of aesthetic surgeries performed on international patients by 2021. The country's reputation, combined with competitive prices compared to neighboring countries, has made it an attractive destination within the EU for medical treatments.

Key players in the aesthetic medicine market

The aesthetic medicine market is defined by a multitude of influential entities, each contributing to the diversity of offerings for consumers seeking non-invasive cosmetic enhancements. Here's a look at the key players shaping this dynamic industry:

  • Injectable manufacturers: These companies are key suppliers in the field of aesthetic medicine, offering products such as botulinum toxins (famous brands include Vistabex, Azzalure and Bocouture) and dermal fillers (including Juvederm Ultra, Ultra Plus, Voluma, Perlane, Restylane and Belotero). Their portfolio typically includes a variety of hyaluronic acid formulations, addressing different cosmetic needs such as wrinkle reduction, lip enhancement and facial contouring.
  • Energy-based equipment suppliers: These manufacturers produce the essential technological devices that doctors use to perform a range of aesthetic treatments. Their inventory covers a range of application-specific machines such as lasers for hair removal, fat reduction devices like cryolipolysis machines, and systems for skin rejuvenation. The full range of solutions they offer is the cornerstone of the diverse procedures available in aesthetic medicine clinics.
  • Cosmeceuticals brands: Like SkinCeuticals, these entities merge the fields of cosmetics and pharmaceuticals, providing highly effective products with high concentrations of active ingredients to complement professional treatments. These cosmeceutical products address a variety of skin problems and help maintain and improve post-procedure results.
  • Independent medical practices: These are establishments where medical professionals offer specialized aesthetic treatments using products and equipment from the aforementioned manufacturers. They are the direct point of contact for consumers seeking aesthetic services, and play a key role in tailoring treatment plans to individual needs.
  • Hospitals and aesthetic centers: In addition to private practices, hospitals and specialized aesthetic centers are the main institutional providers of aesthetic medicine procedures. They often have a multidisciplinary team offering a holistic approach to patient care in the field of aesthetic enhancement.
Get all the information you need
to understand this market

Detailed content

Inforamtion

  • Number of pages : 30 pages
  • Format : Digital and PDF versions
  • Last update : 04/03/2024
Update Details

Summary and extracts

1 Market Summary

1.1 Definition and presentation

The aesthetic medicine and surgery market includes two different segments:

  • Aestheticmedicine: a less invasive branch that does not use surgery to correct a patient's blemishes or defects. Aesthetic medicine treatments are characterized by noninvasive treatments and usually short and painless recovery times.
  • Cosmetic surgery: a branch of plastic surgery that allows a patient's appearance to be improved or physical defects to be permanently eliminated, either totally or partially, through surgeries. Cosmetic surgery procedures are quite invasive, in most cases produce permanent results, and involve longer and more painful recovery times.

This market study focuses mainly on the first segment.

The global cosmetic surgery and medicine market is growing rapidly, and is expected to grow at a CAGR of 11% through 2027. The aesthetic medicine market still remains predominantly dominated by the United States, where a record 5.3 million non-surgical procedures were performed in 2021.

The Italian market is also growing, thanks in particular to the increasing popularity of so-called "non-invasive" methods of aesthetic medicine, placed on the borderline between medical treatment and simple aesthetic procedures. Italy is in fact the country in the world with the highest number of aesthetic medicine procedures in proportion to its population. In recent years, due to covid, this growth has come to a halt from which Italy is recovering more slowly than other countries.

The Italian market is still predominantly driven by women, with 75.8% of procedures, but interest from men has grown in recent years. In fact, it is estimated that requests for non-surgical treatments by men have increased by 25.4 percent since 2008 .

Italians are resorting to aesthetic medicine from an increasingly younger age, as they prefer to prevent the signs of aging, instead of treating them, in the best possible way and with optimal results.

In Italy, the injectables segment dominates the aesthetic medicine market, with 79.8% of all procedures. In fact, Hyaluronic acid fillers and botulinum toxin are the most popular nonsurgical procedures among Italians.

The aesthetic medicine market requires high entry costs and advanced technology , and most manufacturers specialize in manufacturing. The market is constantly renewing, and in recent years there have been major technological advances that have enabled the spread of increasingly less invasive and more effective procedures, such as CoolSculpting and Rhinofiller .

1.2 The global market driven by the United States

The aesthetic medicine and surgery market consists of two segments:

aesthetic medicine (***) cosmetic surgery (***)

The global aesthetic medicine and surgery market was valued at $**.* billion in **** and is expected to grow at a CAGR of **% through ****, reaching a value of $**.* billion at the end of the period.

Market growth is encouraged ...

1.3 Domestic market

According to ISAPS, the Italian market represents *.*% of the global aesthetic medicine and surgery market, which gives us an Italian market size of ***.** million euros (***)

In Italy, the aesthetic medicine segment is one of the most developed in the world, accounting for **.* of the total market. Therefore, we can estimate the ...

1.4 The rise of medical tourism

Medical tourism refers to the phenomenon whereby patients travel abroad to undergo medical treatment. In the past, this term usually referred to those who traveled from developing countries to major medical centers in more developed countries to undergo treatment to which they would not have access in their own country. However, ...

1.5 The impact of Covid

The impact of COVID-** on the aesthetic medicine sector in Italy was significant. Compared to the global average, Italy had a higher percentage of temporarily closed clinics (***). Other consequences include reduced clinic hours, decreased demand for aesthetic treatments due to both safety and virus concerns and loss of income, and increased ...

2 Demand analysis

2.1 Demand remains confined to a small part of the population

Demographics of demand

In Italy, demand for aesthetic medicine treatments has been growing steadily for several decades, thanks to several socio-demographic factors such as an aging population, the increasing importance of physical appearance, the normalization of aesthetic treatments, and the expansion of the male market. As we have seen, the sector ...

2.2 The reasons why Italians turn to cosmetic medicine

The main reason why men and women decide to undergo aesthetic medicine surgery is the need to feel good about themselves: almost * out of ** patients (***) stated this. An interesting fact that reflects the change in our society in recent years is the one related to the importance of image on social ...

2.3 Demand trends

The needs and demands of Italians have changed profoundly in recent years, redefining the existing dynamics within the world of aesthetic medicine and surgery.

There are three main trends in demand: the influence of social media on young people who choose to resort to aesthetic medicine, the growing focus on the ...

2.4 The impact of the Covid-19 emergency on demand

The lockdown caused by the Covid-** pandemic has generated a renewed interest in self-care among Italians. After months of carbohydrate-rich diets, lack of exposure to the sun and outdoors, accumulated stress and the effect of blue light from screens, Italians began to see the effects of the pandemic on their skin. ...

3 Market structure

3.1 A market structured around equipment manufacturers and medical professionals

The value chain of aesthetic medicine includes several stages. First, raw materials are supplied to manufacturers, who process them to produce medical equipment. The latter is then purchased by independent medical practices, hospitals, and aesthetic medicine centers, and is finally used to perform nonsurgical procedures on final patients.

We can distinguish ...

3.2 Production of aesthetic medicine equipment

Aesthetic equipment manufacturing includes the production of injectables, energy-based machinery, and cosmeceuticals. The aesthetics market requires high entry costs and advanced technology , and most manufacturers specialize in producing one of these segments.

The main players in the market international companies, and most production sites are located abroad with the exception of ...

4 Supply analysis

4.1 Overview of the offer

The supply in the aesthetic medicine market can be summarized as follows:

*. Injectables

Botulinum toxin : Botulinum toxin works by inhibiting the release of the neurotransmitter acetylcholine: by blocking its release in the muscles, it reduces excessive facial expressions and thus stops skin sagging, the primary cause of wrinkles and stretch ...

4.2 Injectables segment leading the market

In Italy, the injectables segment dominates the aesthetic medicine market, accounting for **.*% of all procedures. In contrast, facial rejuvenation and other procedures account for only a marginal share of the market, *.*% and **.*%, respectively.

Distribution of the aesthetic medicine market by macro segment Italy, ****, in % Source: ****

Analyzing the distribution of the injectables ...

4.3 Characteristics and prices of procedures

The following table summarizes the characteristics of commercially available nonsurgical aesthetic procedures:

Source: ****

it is important to note that prices vary widely depending on the medical facility, physician, or region.

4.4 Supply trends

The aesthetic medicine market has undergone profound changes in recent years that have been driven by changing customer demand. The supply has adapted to these trends by developing new techniques or advanced machines. Thanks to the continuous technological research conducted by market players, procedures are increasingly dynamic and allow for effective, ...

5 Rules and regulations

5.1 Italian regulations

Title required to perform aesthetic medicine treatments

The aesthetic physician has a degree in Medicine and Surgery , but it is not essential that he or she have any other type of specialization. There is not yet an EEC-compliant University Postgraduate School for aesthetic medicine, and therefore there is not yet a ...

5.2 Off-label prescribing

Any pharmaceutical company that introduces a new drug to the market must have approval from its relevant ministry. The drug is authorized for the particular clinical indication required, calling it "on label." A physician who uses a drug outside of its usual use, uses it out of indication or "off label." ...

6 Positioning of actors

6.1 Segmentation

List of charts

  • Procédures esthétiques chirurgicales et non chirurgicales
  • Évolution du nombre et de la part des interventions non chirurgicales
  • Taille du marché mondial de la médecine et de la chirurgie esthétiques
  • Évolution du marché mondial des interventions esthétiques chirurgicales et non chirurgicales
  • Interventions non chirurgicales par pays
Show more Hide

All our studies are available online in PDF format

Take a look at an example of our research on another market!

Do you have a question about this study?   +44 238 097 0676

Latest news

Ipsen's commitment to the area of rare diseases - 29/02/2024

Performance and strategies of the biopharmaceutical company Ipsen in 2023: 1. **Increase in sales:** In 2023, Ipsen recorded an increase in global sales of 3.4% over the previous year. 2. **Operating margin:** The company recorded an operating margin of 26.1%, which shows an increase of 2% compared to 2022. 3. **Growth factors:** Growth was supported by the company's historical assets, new drugs, pipeline expansion, and accelerated investment in research and development, particularly benefited by recent acquisitions focused on the area of rare diseases. 4. **Entry into the rare disease area:** In 2023, Ipsen acquired Albireo, a leading developer of bile acid modulators for the treatment of pediatric and adult cholestatic liver disease, bringing odevixibat, the first approved treatment against progressive familial intrahepatic cholestasis (Pfic), to the market. 5. **Future Plans:** By 2024, Ipsen plans to launch four innovative therapies worldwide and expand its pipeline, supported by an external innovation strategy in its three core therapeutic areas. 6. **Rare disease commitment:** With new developments such as odevixibat and an evolving pipeline, Ipsen marks its official entry into the rare disease field, aiming to bring therapeutic innovations that can change the course of disease, with a focus on drugs with novel mechanisms of action.

Botox: botulinum toxin boosts pharma's bottom line - 02/08/2023
  • The United States accounts for half of the global botulinum toxin market.
  • Last year, Botox accounted for $5.2 billion in worldwide sales for AbbVie, with equal shares between aesthetics (+21% excluding currency effect) and therapeutics (+13%).
  • In the United States, Dysport (Ipsen) has only 5% of the therapeutic market, compared with 30% in France.
  • In aesthetics in the US, Ipsen has an estimated share of between 20% and 25%.
  • Of the French laboratory Ipsen's half-year sales of 1.5 billion euros (+7%), 319 million (+32%) come from botulinum toxin sold in therapeutics and, in some countries, in aesthetics.
  • Botox holds 40% to 50% of the therapeutic market in France, compared with 30% for Ipsen.
Medicine, Allergan Aesthetics launches training center for healthcare professionals - 26/06/2023

Inauguration of Allergan Aesthetics' Center of Excellence in Italy, specifically in Rome. This center represents the first and only space completely dedicated to both theoretical and practical training of healthcare professionals. Its foundation is supported by the expertise of a multidisciplinary scientific committee composed of 21 nationally and internationally renowned experts. The main goal of the center is to offer high-quality training to healthcare professionals through 4 complementary curricula in order to ensure maximum satisfaction of their patients.

Ipsen exceeds its targets, helped by its Botox competitor - 11/02/2023
  • Family-owned laboratory controlled by descendants of Henri Beaufour
  • Ipsen exceeds its targets
  • Strong growth in sales of Dysport, its botulinum toxin competitor to Botox, generating €594 million in sales
Ipsen bets $1 billion on a biotech to treat liver disease - 21/01/2023
  • Ipsen announces largest acquisition since the sale of Smecta (its family healthcare division) in 2022
  • french pharmaceutical group to launch $952 million takeover bid for US biotech Albireo
  • By 2021, Ipsen has added 16 new molecules to its portfolio
Ipsen strengthens its position in the dynamic rare diseases segment - 09/01/2023
  • Ipsen to pay €1 billion for US biotech Albireo
  • The market for rare diseases is close to $150 billion

Companies quoted in this study

This study contains a complete overview of the companies in the market, with the latest figures and news for each company. :

Fidia Farmaceutici
Decomedical
ITS Group
BTL
EME Estetica
Ipsen
Merz Pharmaceuticals
Allergan plc

Choosing this study means :

Access to more than 35 hours of work

Our studies are the result of over 35 hours of research and analysis. Using our studies allows you to devote more time and added value to your projects.

Benefit from 6 years' experience and over 1,500 industry reports already produced

Our expertise enables us to produce comprehensive studies in all sectors, including niche and emerging markets.

Our know-how and methodology enable us to produce reports that offer unique value for money.

Access to several thousand articles and paid-for data

Businesscoot has access to all the paid economic press as well as exclusive databases to carry out its market research (over 30,000 articles and private sources).

To enhance our research, our analysts also use web indicators (semrush, trends, etc.) to identify market trends and company strategies. (Consult our paying sources)

Guaranteed support after your purchase

A team dedicated to after-sales service, to guarantee you a high level of satisfaction. +44 238 097 0676

A digital format designed for our users

Not only do you have access to a PDF, but also to a digital version designed for our customers. This version gives you access to sources, data in Excel format and graphics. The content of the study can therefore be easily retrieved and adapted for your specific needs.

Our offers :

the aesthetic medicine market | Italy

89 €
  • What are the figures on the size and growth of the market?
  • What is driving the growth of the market and its evolution?
  • What is the positioning of companies in the value chain?
  • Data from several dozen databases

5 reports pack (-15%) IT Italy

75.6 € / study
378 € instead of 445 € -15%
  • 5 reports at €75.6 excluding VAT per study to choose from our Italian catalogue for 12 months
  • Save 15% on additional studies purchased
  • Choose to be refunded any unused credit at the end of the 12-month period (duration of the pack)

See the terms and conditions of the pack and the refund of unused credit.

Updates

  • 04/03/2024 - Lo studio è stato completamente aggiornato da un analista Businesscoot. Oltre a questa revisione completa sono state aggiunte informazioni sui principali attori nel settore con i rispettivi fatturati.
Do you have a question ?
Our team is at your disposal at   +44 238 097 0676